Scinai Immunotherapeutics Ltd., a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, recently announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), has appointed Mr. Eran Kuratz as Head of Supply Chain and Business Process Administration. Mr. Kuratz reports directly to Scinai Chief Executive Officer Amir Reichman.
Mr. Kuratz brings more than 30 years of senior leadership, supply chain and operational experience across the pharmaceutical, biotechnology, medical-device and industrial sectors. He has held senior positions at Kamada, Gamida Cell, OdysightAI, Elite PepsiCo-Frito-Lay and EnvyHer, including roles as CEO, Co-CEO, Director of Supply Chain and Director of Purchasing and Logistics. His experience spans global operations, procurement, logistics, warehousing, enterprise systems and strategic planning in highly regulated environments. Mr. Kuratz is a Practical Engineer in Industrial Engineering and Management from the Technological College of Be’er Sheva.
In his new role, Mr. Kuratz leads Scinai Biopharma Services’ supply chain and key operational support functions, including procurement and contracting, warehousing and inventory management, logistics, budgeting and cost control, bookkeeping administration, and IT and business systems. He is also responsible for enterprise platforms including ERP, CRM and quality-management systems, cybersecurity, and the continuous improvement of cross-functional business processes across the organization.
Amir Reichman, Chief Executive Officer of Scinai, commented:
“Following the expansion of our CDMO platform and the integration of our Jerusalem and Yavne operations, we are increasingly focused on building the systems, processes and organizational infrastructure required to operate effectively at a larger scale. Eran brings extensive experience in supply chain management, operational leadership and enterprise systems, and his appointment creates clear ownership for a number of critical cross-functional processes across the organization. We believe his experience will help us strengthen coordination between our sites and functions, improve operational discipline and establish scalable processes to support the continued growth of our CDMO platform and the broader Scinai organization.”
Scinai expanded its CDMO platform in the first quarter of 2026 through the acquisition of Recipharm Israel from Recipharm AB, adding a second development and manufacturing site in Yavne and significantly broadening both its capacity and technical capabilities. The Jerusalem site is centered on biologics process development and also provides aseptic manufacturing and sterile fill-and-finish capabilities for parenteral injectable products, including both biologics and small molecules. The Yavne site adds complementary capabilities in small-molecule API process development and synthesis, analytical-method development and GMP API manufacturing. Together, the two sites enable Scinai Biopharma Services to support customers across a broader range of development and manufacturing needs. The transaction was also accompanied by a strategic commercial collaboration agreement with Recipharm AB, a global CDMO, extending Scinai’s commercial reach and access to international opportunities.
For other high profile appointments, please check:
Taco John’s Appoints Sarah McAloonto to its Board of Directors
Scale AI Appoints Francis deSouza as CEO
